Xvivo Perfusion AB (publ) (XVIVO.ST)
SEK 320.2
(2.04%)
SEK 320.2
(2.04%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -214.65 Million SEK | 9.25% |
| 2022 | -236.54 Million SEK | 39.81% |
| 2021 | -392.97 Million SEK | -13.5% |
| 2020 | -346.22 Million SEK | -125.41% |
| 2019 | -153.59 Million SEK | 17.54% |
| 2018 | -186.26 Million SEK | 4.49% |
| 2017 | -195.02 Million SEK | -734.46% |
| 2016 | -23.37 Million SEK | 43.04% |
| 2015 | -41.03 Million SEK | 14.87% |
| 2014 | -48.2 Million SEK | -2006.76% |
| 2013 | 2.52 Million SEK | 92.54% |
| 2012 | 1.31 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -463.64 Million SEK | 3.46% |
| 2024 Q3 | -440.14 Million SEK | 2.95% |
| 2024 Q1 | -480.24 Million SEK | -123.73% |
| 2023 FY | -214.65 Million SEK | 9.25% |
| 2023 Q3 | -568.73 Million SEK | -600.39% |
| 2023 Q2 | 113.65 Million SEK | 19.6% |
| 2023 Q4 | -214.65 Million SEK | 62.26% |
| 2023 Q1 | 95.03 Million SEK | 140.18% |
| 2022 Q4 | -236.54 Million SEK | 23.45% |
| 2022 Q1 | -334.64 Million SEK | 14.84% |
| 2022 FY | -236.54 Million SEK | 39.81% |
| 2022 Q3 | -309.01 Million SEK | 0.79% |
| 2022 Q2 | -311.46 Million SEK | 6.93% |
| 2021 FY | -392.97 Million SEK | -13.5% |
| 2021 Q1 | -343.42 Million SEK | 0.81% |
| 2021 Q2 | -305.62 Million SEK | 11.01% |
| 2021 Q3 | -279.84 Million SEK | 8.44% |
| 2021 Q4 | -392.97 Million SEK | -40.43% |
| 2020 Q2 | -92.12 Million SEK | 37.96% |
| 2020 Q3 | -533.88 Million SEK | -479.51% |
| 2020 Q4 | -346.22 Million SEK | 35.15% |
| 2020 Q1 | -148.5 Million SEK | 3.31% |
| 2020 FY | -346.22 Million SEK | -125.41% |
| 2019 Q4 | -153.59 Million SEK | -21.33% |
| 2019 FY | -153.59 Million SEK | 17.54% |
| 2019 Q1 | -121.42 Million SEK | 34.81% |
| 2019 Q2 | -130.86 Million SEK | -7.77% |
| 2019 Q3 | -126.59 Million SEK | 3.26% |
| 2018 Q3 | -160.42 Million SEK | 6.2% |
| 2018 FY | -186.26 Million SEK | 4.49% |
| 2018 Q1 | -163.14 Million SEK | 16.34% |
| 2018 Q2 | -171.02 Million SEK | -4.83% |
| 2018 Q4 | -186.26 Million SEK | -16.11% |
| 2017 FY | -195.02 Million SEK | -734.46% |
| 2017 Q1 | 8.72 Million SEK | 137.35% |
| 2017 Q2 | -174.27 Million SEK | -2096.7% |
| 2017 Q3 | -170.63 Million SEK | 2.09% |
| 2017 Q4 | -195.02 Million SEK | -14.29% |
| 2016 Q1 | -42.72 Million SEK | -4.11% |
| 2016 Q4 | -23.37 Million SEK | 41.65% |
| 2016 Q2 | -41.77 Million SEK | 2.21% |
| 2016 Q3 | -40.05 Million SEK | 4.13% |
| 2016 FY | -23.37 Million SEK | 43.04% |
| 2015 Q1 | -39.66 Million SEK | 17.72% |
| 2015 Q2 | -41.63 Million SEK | -4.98% |
| 2015 Q4 | -41.03 Million SEK | 3.67% |
| 2015 FY | -41.03 Million SEK | 14.87% |
| 2015 Q3 | -42.59 Million SEK | -2.3% |
| 2014 Q1 | 9.68 Million SEK | 283.07% |
| 2014 Q2 | 13.37 Million SEK | 38.15% |
| 2014 Q3 | -55.06 Million SEK | -511.6% |
| 2014 Q4 | -48.2 Million SEK | 12.46% |
| 2014 FY | -48.2 Million SEK | -2006.76% |
| 2013 Q4 | 2.52 Million SEK | -16.07% |
| 2013 Q2 | -1.07 Million SEK | -5.8% |
| 2013 FY | 2.52 Million SEK | 92.54% |
| 2013 Q1 | -1.01 Million SEK | -177.53% |
| 2013 Q3 | 3.01 Million SEK | 379.67% |
| 2012 Q4 | 1.31 Million SEK | 0.0% |
| 2012 FY | 1.31 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Acarix AB (publ) | -35.14 Million SEK | -510.689% |
| ADDvise Group AB (publ) | 1.22 Billion SEK | 117.495% |
| ADDvise Group AB (publ) | 1.22 Billion SEK | 117.495% |
| Arcoma AB | -1.12 Million SEK | -18929.344% |
| Bactiguard Holding AB (publ) | 109.88 Million SEK | 295.347% |
| BICO Group AB (publ) | 927.9 Million SEK | 123.133% |
| Boule Diagnostics AB (publ) | 128.8 Million SEK | 266.655% |
| CellaVision AB (publ) | -56.94 Million SEK | -276.964% |
| Clinical Laserthermia Systems AB (publ) | -14.87 Million SEK | -1342.838% |
| Chordate Medical Holding AB (publ) | -8.45 Million SEK | -2438.683% |
| C-Rad AB (publ) | -127.6 Million SEK | -68.222% |
| Duearity AB (publ) | 10.23 Million SEK | 2198.045% |
| Dignitana AB (publ) | 13.07 Million SEK | 1741.439% |
| Episurf Medical AB (publ) | -52.7 Million SEK | -307.307% |
| Getinge AB (publ) | 5.4 Billion SEK | 103.969% |
| Scandinavian Real Heart AB (Publ) | -35.05 Million SEK | -512.36% |
| Iconovo AB (publ) | -10.75 Million SEK | -1895.763% |
| Integrum AB (publ) | -10.47 Million SEK | -1948.874% |
| Luxbright AB (publ) | -13.83 Million SEK | -1451.679% |
| Mentice AB (publ) | -49.56 Million SEK | -333.078% |
| OssDsign AB (publ) | -162.78 Million SEK | -31.859% |
| Paxman AB (publ) | -11.41 Million SEK | -1781.088% |
| Promimic AB (publ) | -50.32 Million SEK | -326.547% |
| Qlife Holding AB (publ) | 19.07 Million SEK | 1225.595% |
| SciBase Holding AB (publ) | -27.32 Million SEK | -685.577% |
| ScandiDos AB (publ) | -1.53 Million SEK | -13920.314% |
| Sectra AB (publ) | -772.85 Million SEK | 72.226% |
| Sedana Medical AB (publ) | -226.87 Million SEK | 5.388% |
| Senzime AB (publ) | -139.54 Million SEK | -53.826% |
| SpectraCure AB (publ) | -50.23 Million SEK | -327.302% |
| Stille AB | -178.5 Million SEK | -20.25% |
| Vitrolife AB (publ) | 1.22 Billion SEK | 117.48% |